Melphalan flufenamide (Pepaxto; Oncopeptides AB) in combination with dexamethasone was granted accelerated approval on February 26, 2021, by the FDA for adult patients with relapsed or refractory multiple myeloma.
Samantha Troy, 2021 PharmD candidate
Advertisement
Samantha Troy is a 2021 PharmD candidate at the University of Connecticut School of Pharmacy in Storrs.
Articles by Samantha Troy, 2021 PharmD candidate
Advertisement
Latest Updated Articles
Melphalan Flufenamide for Relapsed or Refractory Multiple MyelomaPublished: May 11th 2021 | Updated:
Advertisement
Advertisement
Trending on Drug Topics
1
FDA Approves Afibercept-Boav as Biosimilar to Afibercept for Diabetic Macular Edema
2
CVS Pharmacy Acquires Select Rite Aid Assets in 3 States, Accounting for Over 600 Stores
3
FDA Approves Risperidone Injection for Bipolar I Disorder in Adults
4
Vaccine Messaging for Teens Should Tailor to Personal Perspectives
5
